MabQuest Therapeutics

MabQuest Therapeutics is a Swiss biotechnology company focused on developing a novel class of allosteric monoclonal antibodies for cancer immunotherapy. Unlike conventional orthosteric PD-1 inhibitors that block the PD-1/PD-L1 interaction, MabQuest's lead candidates utilize a unique mechanism of action to promote T-cell recovery from exhaustion without necessarily blocking the ligand interaction. This approach allows for potential combination therapies with existing checkpoint inhibitors and may provide efficacy in patients with low PD-L1 expression. The company's lead asset, MAQ-001, is currently in Phase 1 clinical trials for advanced solid tumors.